RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
|Source||Oncol Rep (2017). Figure 2. Ro3280|
|Cell Lines||NB4 cells|
|Concentrations||200 and 500 nM|
|Incubation Time||4 h|
|Results||Western blotting showed more LC3-II in NB4 cells treated with RO3280 and BI2536. More LC3-II was observed in the 100-500 nM RO3280 group and in the 200-500 nM BI2536 group|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 90 mg/mL|
|Related PLK Products|
HMN-176 inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.
ON1231320, also known as GBO-006, is a Polo-like kinase 2 (PLK2) inhibitor. In vitro testing revealed that ON1231320 is a selective inhibitor of PLK2 with no inhibitory activity against PLK1, PLK3 and PLK4.
SBE13 hydrochloride is a potent and selective PLK1 inhibitor.
HMN-214 is a procompound of HMN-176, which alters the cellular spatial orientation of Plk1.
TAK-960 is a novel, potent and selective Plk1 inhibitor with IC50 of 8 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.